18 May 2023 in Regulatory Toxicology and Pharmacology
26 July 2022 in Archives of Toxicology
20 October 2024 in Regulatory Toxicology and Pharmacology
9 July 2025 in Journal of Environmental Science and Health, Part C
Luteolin and apigenin, which are abundantly present in various vegetables, fruits, and herbs, have emerged as noteworthy candidates for therapeutic applications. Traditionally recognized for their anti-inflammatory and antioxidant activities, both luteolin and apigenin have recently demonstrated the ability to inhibit cancer cell growth across multiple cancer types in vitro and in animal models. This review provides a comprehensive summary of in vivo evidence supporting the anticancer effects of luteolin and apigenin, highlighting their mechanisms of action. The review encompasses studies on their effects on liver, lung, gastric, colon, breast, pancreatic, prostate, and skin cancers in animals. We also discuss the toxicity profiles of luteolin and apigenin. Despite the encouraging preclinical results, neither luteolin nor apigenin has yet been proven to be an effective agent against cancer in clinical trials. Therefore, this review also addresses the current challenges in translating the promising anticancer effects of flavones into clinical success, emphasizing the need for further research using advanced animal models and appropriate administration routes to increase the translational value of preclinical studies. This literature review aims to enhance understanding of the anticancer and toxicological effects of luteolin and apigenin, rather than serving as a risk assessment.
20 June 2024 in Cancer Epidemiology, Biomarkers & Prevention
Background: Pancreatic cancer is among the most fatal human cancers and the fourth leading cause of cancer death in the United States. Evidence suggests that chronic inflammation may play a role in pancreatic carcinogenesis and its inhibition through nonsteroidal anti-inflammatory drugs (NSAID) may reduce pancreatic cancer incidence. Methods: We examined associations of total and individual NSAIDs with pancreatic cancer risk among postmenopausal women participating in the Women’s Health Initiative observational study and clinical trial cohorts. Among 117,452 women, aged 55 to 79 years, 727 incident pancreatic cancer cases were reported over 18 years of follow-up. Cox regression was used to estimate hazard ratio (HR) and 95% confidence interval (CI) for associations between NSAIDs and pancreatic cancer risk. Results: Relative to non-use, consistent use of any NSAID was inversely associated with pancreatic cancer risk (HR 0.71, 95% CI, 0.59–0.87), primarily driven by strong associations for aspirin use (HR 0.67, 95% CI, 0.52–0.86). Use of total or individual non-aspirin NSAIDs was not associated with pancreatic cancer. Upon stratified analysis, we observed stronger associations for NSAIDs among participants with prevalent diabetes (HR 0.28, 95% CI, 0.10–0.75) relative to those without (HR 0.75, 95% CI, 0.61–0.92; P-interaction = 0.03). Conclusions: Additional large prospective studies with careful measurement of NSAID type, dose, and frequency are needed to further investigate the possibility of added benefit among individuals diagnosed with diabetes. Impact: This study adds to existing evidence from prospective studies and clinical trials suggesting that use of aspirin may provide moderate benefit for pancreatic cancer prevention.
1 February 2025 in Toxicology